

### EMPIRIC CHOICE

- ✦ Oseltamivir is used for the prevention of influenza infection as determined by Infection Prevention and Control. This may occur during an influenza outbreak or to prevent isolated nosocomial infection.

### ROUTE

- ✦ Enteral (PO/NG/OG)

### DOSE

Creatinine clearance	Dose and Frequency
>60 mL/min	75 mg once daily
30-60 mL/min	30 mg once daily
10-29mL/min	30 mg every other day
<10 mL/min	30 mg once weekly
Patients receiving dialysis	Sustained low-efficiency dialysis (SLED): 30 mg after each dialysis session, consider 75mg once daily in continuous/24h SLED*
	Hemodialysis (HD), high-flux: 30 mg immediately, then 30 mg after each hemodialysis session
	Peritoneal Dialysis (PD): 30 mg once weekly
	Continuous Renal Replacement Therapy (CRRT), high-flux: 30 mg once daily

\*Limited data extrapolated from treatment dosing

### DURATION

- ✦ Prophylaxis: until influenza outbreak declared over and/or as recommended by Infection Prevention and Control, usually 8-10 days
- ✦ Patients with CrCl < 10 ml/min or those receiving PD, once weekly dosing provides sufficient exposure. If therapy is to continue beyond 7 days, repeat dosing is required.

### ALTERNATIVES FOR ALLERGIES

- ✦ Allergy to oseltamivir is uncommon. If present, consultation should be obtained from Infectious Diseases (ID)

### COMMON ORGANISMS

- ✦ Influenza A and B

### CURRENT RESISTANCE ISSUES

- ✦ Drug resistance is rare but, if considered, consultation should be obtained from Infectious Diseases (ID)

### IMMUNOCOMPROMISED HOST CONSIDERATION

- ✦ Immunocompromised patients may be especially vulnerable to influenza infection and should be monitored for signs and symptoms of influenza despite taking oseltamivir prophylaxis.

### ADDITIONAL DIAGNOSTIC AND THERAPEUTIC COMMENTS

- ✦ Prophylaxis with oseltamivir is not universally effective. Treatment with oseltamivir is warranted should influenza occur while on prophylaxis.
- ✦ While both baloxavir marboxil and peramivir are newly available in Canada, clinical use criteria are not yet available and neither drug is on formulary at Sinai Health or University Health Network

**Disclaimer:** This document is intended for internal use at Sinai Health System and University Health Network. Recommendations herein are based on existing literature and clinical practice and are subject to change at any time. Please refer to the [Terms and Conditions](#) for more details.

## REFERENCES

1. Aoki, F.Y., et al., *Use of antiviral drugs for seasonal influenza: Foundation document for practitioners-Update 2019*. J Assoc Med Microbiol Infect Dis Can, 2019. **4**(2): p. 60-82.
2. Uyeki, T.M., et al., Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis, 2019. 68(6): p. 895-902.
3. Aoki, F.Y., et al., *2021-2022 AMMI Canada guidance on the use of antiviral drugs for influenza in the COVID-19 pandemic setting in Canada*. J Assoc Med Microbiol Infect Dis Can, 2022. **7**(1): p. 1-7.
4. Patel, K., et al., *Pharmacokinetics and safety of oseltamivir in patients with end-stage renal disease treated with automated peritoneal dialysis*. Br J Clin Pharmacol, 2015. **79**(4): p. 624-35.
5. Tamiflu® (oseltamivir) [Product Monograph] Mississauga, Ontario Canada. Hoffman-Laroche Ltd. 2022.
6. Lexi-Drugs/Oseltamivir. Lexicomp app. Accessed January 9, 2022.
7. Oseltamivir, in The Renal Drug Handbook, A. C, Editor. 2019, CRC Press, Taylor and Francis Group: Boca Raton, FL. p. 747-748.